Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;7(6):R953-64.
doi: 10.1186/bcr1325. Epub 2005 Oct 3.

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

Yudi Pawitan  1 , Judith Bjöhle, Lukas Amler, Anna-Lena Borg, Suzanne Egyhazi, Per Hall, Xia Han, Lars Holmberg, Fei Huang, Sigrid Klaar, Edison T Liu, Lance Miller, Hans Nordgren, Alexander Ploner, Kerstin Sandelin, Peter M Shaw, Johanna Smeds, Lambert Skoog, Sara Wedrén, Jonas Bergh
Affiliations

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

Yudi Pawitan et al. Breast Cancer Res. 2005.

Abstract

Introduction: Adjuvant breast cancer therapy significantly improves survival, but overtreatment and undertreatment are major problems. Breast cancer expression profiling has so far mainly been used to identify women with a poor prognosis as candidates for adjuvant therapy but without demonstrated value for therapy prediction.

Methods: We obtained the gene expression profiles of 159 population-derived breast cancer patients, and used hierarchical clustering to identify the signature associated with prognosis and impact of adjuvant therapies, defined as distant metastasis or death within 5 years. Independent datasets of 76 treated population-derived Swedish patients, 135 untreated population-derived Swedish patients and 78 Dutch patients were used for validation. The inclusion and exclusion criteria for the studies of population-derived Swedish patients were defined.

Results: Among the 159 patients, a subset of 64 genes was found to give an optimal separation of patients with good and poor outcomes. Hierarchical clustering revealed three subgroups: patients who did well with therapy, patients who did well without therapy, and patients that failed to benefit from given therapy. The expression profile gave significantly better prognostication (odds ratio, 4.19; P = 0.007) (breast cancer end-points odds ratio, 10.64) compared with the Elston-Ellis histological grading (odds ratio of grade 2 vs 1 and grade 3 vs 1, 2.81 and 3.32 respectively; P = 0.24 and 0.16), tumor stage (odds ratio of stage 2 vs 1 and stage 3 vs 1, 1.11 and 1.28; P = 0.83 and 0.68) and age (odds ratio, 0.11; P = 0.55). The risk groups were consistent and validated in the independent Swedish and Dutch data sets used with 211 and 78 patients, respectively.

Conclusion: We have identified discriminatory gene expression signatures working both on untreated and systematically treated primary breast cancer patients with the potential to spare them from adjuvant therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Description of exclusion criteria for all patients (pts) operated on for primary breast cancer at (a) Karolinska Hospital, 1994–1996 and (b) Uppsala University Hospital, 1987–1989.
Figure 2
Figure 2
Unsupervised hierarchical clustering of the Stockholm cohort (n = 159) using the 64-gene set. Each column refers to a patient and each row to a gene. Red indicates a high value of gene expression, and green indicates a low value. The list of genes is presented in Additional file 1, in the same order as they appear on the plot. Risk.score, computed by linear discriminant analysis and used here only to describe the clusters. Status.5 yr, black if the corresponding patient had distant metastasis or died within 5 years. BRCA.5 yr, black if the death was due to breast cancer. NodePos, black if the corresponding patient was lymph-node-positive; Grade3, black if the patient had Elston grade 3.
Figure 3
Figure 3
Supervised clustering of the node-positive treated cohort in Uppsala (n = 76) using the 64-gene set. The accompanying variables have the same meaning as in Fig. 2.
Figure 4
Figure 4
Supervised clustering of the node-negative untreated cohort in Uppsala (n = 135) using the 64-gene set. The accompanying variables have the same meaning as in Fig. 2.
Figure 5
Figure 5
Supervised clustering of the van't Veer cohort (n = 78) using 42 genes of the 64-gene set. Meta.5 yr, black if the patient had distant metastasis within 5 years.
Figure 6
Figure 6
Kaplan–Meier survival curves of the risk clusters found in (a) the Stockholm cohort, (b) the Uppsala treated cohort, (c) the Uppsala untreated cohort and (d) the van't Veer cohort. L, low-risk group; M, medium-risk group; H, high-risk group. The P value in each plot, computed in a Cox regression, is for simultaneous comparison of all three curves for the whole follow-up period.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467. doi: 10.1016/S0140-6736(97)11423-4. - DOI - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942. doi: 10.1016/S0140-6736(98)03301-7. - DOI - PubMed
    1. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer? [comment] Lancet. 2000;355:944–945. doi: 10.1016/S0140-6736(00)90007-2. - DOI - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355:1757–1770. doi: 10.1016/S0140-6736(00)02263-7. - DOI - PubMed
    1. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360:1131–1135. doi: 10.1016/S0140-6736(02)11199-8. - DOI - PubMed

Publication types